What type of study is this?

This is a Systematic Review study.

Advancing gastric cancer treatment: A comprehensive review of hyperthermic intraperitoneal chemotherapy’s role and outcomes

View Full Paper

Ask AI

Bookmark

HIPEC may improve overall survival in selected patients with advanced gastric cancer compared to systemic therapy alone.
Thirteen prospective studies showed a median overall survival of 11-24.9 months in therapeutic HIPEC settings.
Cytoreductive surgery combined with HIPEC achieved disease-free survival and reduced peritoneal recurrence, especially in high-risk cases.
Need for further standardization and additional prospective trials to confirm HIPEC's benefits in gastric cancer treatment.

No takes yet. Share an insight, caveat, or question.

Systematic review evaluates hyperthermic intraperitoneal chemotherapy outcomes in gastric cancer, suggesting benefits.

D’Acapito et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark